IMMUNITY ASSESSED
PERSONALIZED TREATMENT

Guide your therapeutic strategy and patient discussion with the most accurate information based on immune system response.

Immunoscore® is included in the ESMO Clinical Practice Guidelines 2020 for Localised Colon Cancer.
WHAT IS IMMUNOSCORE® *

Decades of in-depth research has led to an appreciation for the role of the immune system in the evolution of colorectal cancer. A paradigm shift is occurring in the assessment of tumor-infiltrating lymphocytes (TILs) for prognostication and prediction of benefit from adjuvant therapies, with the emergence of a new clinical biomarker, the Immunoscore®. By measuring the host immune response at the tumor site, the in vitro diagnostic test predicts the risk of relapse in localized colon cancer patients.

Immunoscore® has demonstrated its prognostic performance in a large international SITC-led study (n=2,681). Using it in addition to the TNM classification, it refines the patient’s risk profile.

ADD RESOLUTION TO YOUR TRADITIONAL RISK ASSESSMENT TOOLS

Pagès F et al. The Lancet 2018

Personalize your patients’ treatment by assessing their immune response.

*CE-IVD for European Community countries, performed in CLIA certified laboratory for the US
**Refine the risk profile of stage II patients**

**Prognostic value of Immunoscore® in stage II:**

Validated on the international SITC study among Stage II patients (n = 1,434), Immunoscore® assesses relapse risk in stage II colon cancer patients (5-year recurrence risk: IS Low=28% vs IS High= 13%) and identifies patients for whom surgery would be sufficient.

<table>
<thead>
<tr>
<th>Patient without event (%)</th>
<th>Time to recurrence (Years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low clinical risk patients: 50/500 (44.25%) 5Y: 89.1 (86.1-92.1)</td>
<td></td>
</tr>
<tr>
<td>High clinical risk + IS High (2-3-4)</td>
<td>49/438 (38.76%) 5Y: 87.4 (83.9-91)</td>
</tr>
<tr>
<td>High clinical risk + IS Low (0-1)</td>
<td>49/192 (16.99%) 5Y: 72.2 (65.6-79.6)</td>
</tr>
</tbody>
</table>

TTR in Stage II untreated patients according to clino-pathological risk (n=1130)

- 70% of patients with high clinical risk might be spared chemotherapy.

**Immunoscore® is more informative than traditional risk assessment tools and clearly identifies patients who could be spared chemotherapy.**

**Choose the best treatment duration for stage III patients**

**Prognostic & predictive value of Immunoscore® in stage III:**

Demonstrated on the prospective IDEA France study (n=1062):
- Immunoscore Low: 3-year DFS= 67% [95%CI 62–71]
- Immunoscore High: 3-year DFS=77% [95%CI 74–80]

Similar prognostic results obtained in the FOLFOX arm of NCCTG N0147 prospective clinical trial.

**Immunoscore® prediction of FOLFOX efficacy (n=973)**

<table>
<thead>
<tr>
<th>Disease-Free Survival Probability</th>
<th>Time since random assignment (Years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IS Low (0-1) Patients</td>
<td>6 months FOLFOX (N=206)</td>
</tr>
<tr>
<td>IS High (2-3-4) Patients</td>
<td>6 months FOLFOX (N=275)</td>
</tr>
</tbody>
</table>

**Survival is driven by Immunoscore® regardless MSI/MSS status**

**The Immunoscore® predicts response to longer duration of FOLFOX treatment in stage III colon cancer patients whatever the clinical risk.**

Demonstrated in over 6000 patients
IMMUNOSCORE® WORKFLOW

Immunoscore® is available as a full service solution (performed at HalioDx CLIA laboratories).

* Easy ordering
* Clinically validated cut-offs
* Accuracy through digital pathology
* Reliable & reproducible result
* Turn-around time compatible with post-surgery decision

Patient post resection surgery

Tumor block or unstained slides

Stain & Scan Slides

Compute Immunoscore®

Report Immunoscore® results

---

Pathology lab

HalioDx lab

10 working days after receipt of specimen

Sales support
For commercial questions, please contact:
infos@haliodx.com

Medical support
For support to interpret the results, please contact:
customer.care@haliodx.com

Technical support
For technical support, please contact:
tech.support@haliodx.com
REFERENCE PUBLICATIONS

Pages F, Andre T, Taieb J et al.
J Clin Oncol. 2019; 37 (no. 15_suppl)

Pagès F, Mlecnik B, Marliot F et al.
Lancet. 2018; 391 (10135)

Sinicrope F, Shi Q, Hermitte F et al.
J Clin Oncol. 2018; 36:4s (suppl; abstr 614)

Sinicrope F, Shi Q, Hermitte F et al.
J Clin Oncol. 2017; 35:15s (suppl; abstr 3579)

Mlecnik B, Bindea G, Angell HK et al.
Immunity. 2016;15:44(3)

Kirillovsky A, Marliot F, El Sissy C et al.
Int Immunol. 2016;28(8)

Mlecnik B, Tosolini M, Kirillovsky A et al.
J Clin Oncol. 2011;29(6)

Pagès F, Kirillovsky A, Mlecnik B et al.
J Clin Oncol. 2009;27(35)

Galon J, Costes A, Sanchez-Cabo F et al.
Science. 2006;313(5795)

Sinicrope F, Shi Q, Hermitte F et al.
JNCI Cancer Spectrum 2020 4(3): pkaa023

Pages F, Andre T, Taieb J et al.
Ann Oncol. 2020 Apr 12